Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Hagman said doctors might want to consider prescribing GLP-1 weight loss drugs like Wegovy and Zepbound to children with obesity, based on these results. Those drugs are rarely used in children. “I’m ...

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman (pictured, above) as chief commercial officer (CCO). In this role, Ms Coleman will be responsible for ...

Other GLP-1 receptor agonist drugs already on the market for obesity include Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound.

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch ...

compared to a 22.5% weight loss achieved by Lilly’s obesity treatment Zepbound over 72 weeks. The latest trial results of Lilly’s next-generation drug, retatrutide, demonstrated an average ...

In addition to the two main analyses, Akero shared a subgroup analysis to show how EFX performed in people who weren’t taking GLP-1 drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.

and tirzepatide (Zepbound, Eli Lilly) for the treatment of diabetes or obesity that reported on changes in fat mass, lean mass or bone mineral density as measured by DXA scan. Researchers found ...